[Support for Coronavirus Disease 2019 Comparator Vaccines and Research Vaccines]

Protecting people's health and lives through vaccination is crucial in the event of an infectious disease such as coronavirus disease 2019 (COVID-19). Vaccines are a cost-effective way of preventing infectious diseases and their spread. The absence of domestic companies capable of rapidly developing and supplying vaccines that are effective in responding to infectious diseases can lead to supply and demand instability and disruption of smooth vaccination owing to increasing external dependence on vaccine supplies. Therefore, it is necessary to support domestic companies and research institutes that are developing vaccines, so that effective and safe vaccines can be quickly and stably supplied to prevent infectious diseases. To support domestic pharmaceutical companies and research institutes that are researching and developing COVID-19 follow-up vaccines, this article will explain the overall project to provide free comparator vaccines from clinical trials and from research studies by using the surplus of the COVID-19 vaccines purchased by the government, as well as the achievements, limitations, and improvement plans.